당뇨병성 황반부종 시장 규모 : 치료 유형별, 용도별, 최종사용자별 - 지역별 전망, 경쟁 전략 및 부문 예측(-2033년)

Diabetic Macular Edema Market Introduction and Overview

According to SPER market research, 'Diabetic Macular Edema Market Size- By Treatment Type, By Application, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Diabetic Macular Edema Market is predicted to reach USD 15.25 billion by 2033 with a CAGR of 4.69%.

One of the most frequent reasons of diabetic vision loss is diabetes-related macular edema (DME). It is believed to be brought on by the hyper permeability of the retinal vasculature. Macular edema and the severity of diabetic retinopathy are related. Due to the complexity of the pathophysiology and molecular mechanisms behind the development of diabetic macular edema, a deeper understanding of the disease's molecular pathways and pathogenesis is required.

The COVID-19 virus first surfaced in December 2019 and has since spread to nearly every country in the world, prompting the World Health Organisation (WHO) to declare a public health emergency. The global healthcare system has been badly disrupted in the aftermath of the coronavirus pandemic due to the financial crisis and the delay in delivering specialist healthcare while prioritising COVID-19 treatments.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Treatment Type, By Application, By End User

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Abbvie Inc., Alimera Sciences Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Kubota Pharmaceutical,Hodlings Co. Ltd., Novartis AG, Regen X Bio Inc., Regeneron Pharmaceuticals Inc.,

Global Diabetic Macular Edema Market Segmentation:

By Treatment Type: Based on the Treatment Type, Global Diabetic Macular Edema Market is segmented as; Drug Therapy and Laser Treatment.

By Application: Based on the Application, Global Diabetic Macular Edema Market is segmented as; Macular Edema and Macular Degeneration.

By End User: Based on the End User, Global Diabetic Macular Edema Market is segmented as; Hospital, Clinics and Other.

Table of Contents

1. Introduction

• 1.1. Scope of the report
• 1.2. Market segment analysis

2. Research Methodology

• 2.1. Research data source
  • 2.1.1. Secondary Data
  • 2.1.2. Primary Data
  • 2.1.3. SPER's internal database
  • 2.1.4. Premium insight from KOL's
• 2.2. Market size estimation
  • 2.2.1. Top-down and Bottom-up approach
• 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

• 4.1. Driver, Restraint, Opportunity and Challenges analysis
  • 4.1.1. Drivers
  • 4.1.2. Restraints
  • 4.1.3. Opportunities
  • 4.1.4. Challenges
• 4.2. COVID-19 Impacts of the Global Diabetic Macular Edema Market

5. Market variable and outlook

• 5.1. SWOT Analysis
  • 5.1.1. Strengths
  • 5.1.2. Weaknesses
  • 5.1.3. Opportunities
  • 5.1.4. Threats
• 5.2. PESTEL Analysis
  • 5.2.1. Political Landscape
  • 5.2.2. Economic Landscape
  • 5.2.3. Social Landscape
  • 5.2.4. Technological Landscape
  • 5.2.5. Environmental Landscape
  • 5.2.6. Legal Landscape
• 5.3. PORTER's Five Forces
  • 5.3.1. Bargaining power of suppliers
  • 5.3.2. Bargaining power of buyers
  • 5.3.3. Threat of Substitute
  • 5.3.4. Threat of new entrant
  • 5.3.5. Competitive rivalry
• 5.4. Heat Map Analysis

6. Competitive Landscape

• 6.1. Global Diabetic Macular Edema Market Manufacturing Base Distribution, Sales Area, Product Type
• 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Diabetic Macular Edema Market

7. Global Diabetic Macular Edema Market, By Treatment Type (USD Million)

• 7.1. Global Diabetic Macular Edema Market Value Share and Forecast, By Treatment Type, 2024-2033
• 7.2. Drug Therapy
• 7.3. Laser Treatment

8. Global Diabetic Macular Edema Market, By Application (USD Million)

• 8.1. Global Diabetic Macular Edema Market Value Share and Forecast, By Application, 2024-2033
• 8.2. Macular Edema
• 8.3. Macular Degeneration

9. Global Diabetic Macular Edema Market, By End User (USD Million)

• 9.1. Global Diabetic Macular Edema Market Value Share and Forecast, By End User, 2024-2033
• 9.2. Hospital
• 9.3. Clinics
• 9.4. Others

10. Global Diabetic Macular Edema Market Forecast, 2020-2033 (USD Million)

• 10.1. Global Diabetic Macular Edema Market Size and Market Share

11. Global Diabetic Macular Edema Market, By Treatment Type 2020-2033 (USD Million)

• 11.1. Global Diabetic Macular Edema Market Size and Market Share By Treatment Type (2020-2026)
• 11.2. Global Diabetic Macular Edema Market Size and Market Share By Treatment Type (2027-2033)

12. Global Diabetic Macular Edema Market, By Application, 2020-2033 (USD Million)

• 12.1. Global Diabetic Macular Edema Market Size and Market Share By Application (2020-2026)
• 12.2. Global Diabetic Macular Edema Market Size and Market Share By Application (2027-2033)

13. Global Diabetic Macular Edema Market, By End User, 2019-2033 (USD Million)

• 13.1. Global Diabetic Macular Edema Market Size and Market Share By End User (2020-2026)
• 13.2. Global Diabetic Macular Edema Market Size and Market Share By End User (2027-2033)

14. Global Diabetic Macular Edema Market, By Region, 2019-2033 (USD Million)

• 14.1. Global Diabetic Macular Edema Market Size and Market Share By Region (2020-2026)
• 14.2. Global Diabetic Macular Edema Market Size and Market Share By Region (2027-2033)
• 14.3. Asia-Pacific
  • 14.3.1. Australia
  • 14.3.2. China
  • 14.3.3. India
  • 14.3.4. Japan
  • 14.3.5. South Korea
  • 14.3.6. Rest of Asia-Pacific
• 14.4. Europe
  • 14.4.1. France
  • 14.4.2. Germany
  • 14.4.3. Italy
  • 14.4.4. Spain
  • 14.4.5. United Kingdom
  • 14.4.6. Rest of Europe
• 14.5. Middle East and Africa
  • 14.5.1. Kingdom of Saudi Arabia
  • 14.5.2. United Arab Emirates
  • 14.5.3. Rest of Middle East & Africa
• 14.6. North America
  • 14.6.1. Canada
  • 14.6.2. Mexico
  • 14.6.3. United States
• 14.7. Latin America
  • 14.7.1. Argentina
  • 14.7.2. Brazil
  • 14.7.3. Rest of Latin America

15. Company Profile

• 15.1. Alimera Sciences Inc.
  • 15.1.1. Company details
  • 15.1.2. Financial outlook
  • 15.1.3. Product summary
  • 15.1.4. Recent developments
• 15.2. Abbvie Inc.
  • 15.2.1. Company details
  • 15.2.2. Financial outlook
  • 15.2.3. Product summary
  • 15.2.4. Recent developments
• 15.3. Bayer AG
  • 15.3.1. Company details
  • 15.3.2. Financial outlook
  • 15.3.3. Product summary
  • 15.3.4. Recent developments
• 15.4. Bausch Health Companies Inc.
  • 15.4.1. Company details
  • 15.4.2. Financial outlook
  • 15.4.3. Product summary
  • 15.4.4. Recent developments
• 15.5. F. Hoffmann-La Roche Ltd
  • 15.5.1. Company details
  • 15.5.2. Financial outlook
  • 15.5.3. Product summary
  • 15.5.4. Recent developments
• 15.6. GlaxoSmithKline Plc
  • 15.6.1. Company details
  • 15.6.2. Financial outlook
  • 15.6.3. Product summary
  • 15.6.4. Recent developments
• 15.7. Kubota Pharmaceutical Hodlings Co. Ltd.
  • 15.7.1. Company details
  • 15.7.2. Financial outlook
  • 15.7.3. Product summary
  • 15.7.4. Recent developments
• 15.8. Novartis AG
  • 15.8.1. Company details
  • 15.8.2. Financial outlook
  • 15.8.3. Product summary
  • 15.8.4. Recent developments
• 15.9. Regen X Bio Inc.
  • 15.9.1. Company details
  • 15.9.2. Financial outlook
  • 15.9.3. Product summary
  • 15.9.4. Recent developments
• 15.10. Regeneron Pharmaceuticals Inc.
  • 15.10.1. Company details
  • 15.10.2. Financial outlook
  • 15.10.3. Product summary
  • 15.10.4. Recent developments
• 15.11. Others

16. List of Abbreviations

17. Reference Links

18. Conclusion

19. Research Scope